IP Library › Granted Patent US 12,416,034
Granted Patent B2
US 12,416,034 · App. 18/132,027 · Granted Sep 16, 2025

Recombinant production of steviol glycosides

Inventors: Jens Houghton-Larsen (Birkerod, DK); Paula Hicks (Bend, OR); Michael Naesby (Huninque, FR); Thomas Tange Ostergaard (Reihen, CH); Jorgen Hansen (Frederiksberg, DK); Michael Mikkelsen Dalgaard (Vaerlose, DK); Esben Hansen-Halkjaer (Frederiksberg, DK); Ernesto Simon (Glostrup, DK); Sabina Tavares (Basel, CH)
Assignee: Danstar Ferment AG
C12P19/56C12N9/0032C12N9/0071C12N9/0073C12N9/1051C12N9/1085C12N9/88C12N9/90C12N15/63C12N15/81C12N15/8243C12P19/44Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,416,034
App. No.
18/132,027
Granted
Sep 16, 2025
Kind
B2
Abstract

Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express recombinant genes encoding UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce steviol glycosides, e.g., Rebaudioside A and/or Rebaudioside D, which can be used as natural sweeteners in food products and dietary supplements.

Claims (77)

1. A method for producing a target steviol glycoside or a target steviol glycoside composition, comprising contacting a starting composition comprising a precursor steviol glycoside having a 13-O-glucose, a 19-O-glucose, or both a 13-O-glucose and a 19-O-glucose, and/or a mixture thereof with a first recombinant uridine 5′-diphospho (UDP) glycosyl transferase polypeptide capable of beta 1,2 glycosylation of a C2′ of the 13-O-glucose, the 19-O-glucose, or both the 13-O-glucose and the 19-O-glucose of the precursor steviol glycoside and having at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 152 and one or more sugar moiety donor, under suitable reaction conditions to transfer one or more sugar moieties from the one or more sugar moiety donor to the precursor steviol glycoside, thereby producing the target steviol glycoside or the target steviol glycoside composition;

wherein the precursor steviol glycoside is steviol-13-O-glucoside, rubusoside, stevioside or rebaudioside A;

wherein the target steviol glycoside is or the target steviol glycoside composition comprises stevioside, rebaudioside E, rebaudioside D, steviol-1,2 bioside, steviol-1,2-xylobioside, steviol-1,2-rhamnobioside, or an isomer thereof;

wherein the first recombinant 5′-UDP glycosyl transferase polypeptide is capable of converting Rebaudioside A (RebA) to Rebaudioside D (RebD) at a rate that is at least 20 times faster than the rate at which a UDP glycosyl transferase polypeptide having the amino acid sequence set forth in SEQ ID NO:5 is capable of converting RebA to RebD under corresponding reaction conditions; and/or

wherein the first recombinant 5′-UDP glycosyl transferase polypeptide is capable of converting higher amounts of RebA to RebD compared to the UDP glycosyl transferase polypeptide having the amino acid sequence set forth in SEQ ID NO:5 under corresponding reaction conditions.

2. The method of claim 1 , wherein:

(a) the precursor steviol glycoside is rubusoside, wherein the additional sugar moiety is glucose, and stevioside is produced upon transfer of the additional glucose moiety;

(b) the precursor steviol glycoside is stevioside, the additional sugar moiety is glucose, and rebaudioside E is produced upon transfer of the additional glucose moiety;

(c) the precursor steviol glycoside is stevioside, the additional sugar moiety is glucose, the stevioside is contacted with the polypeptide capable of beta 1,2 glycosylation of the C2′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of a steviol glycoside and a polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose of a steviol glycoside, and rebaudioside D is produced upon transfer of the additional glucose moiety;

(d) the precursor steviol glycoside is steviol-13-O-glucoside, the additional sugar moiety is glucose, and steviol-1,2 bioside is produced upon transfer of the additional glucose moiety;

(e) the precursor steviol glycoside is steviol-13-O-glucoside, the additional sugar moiety is xylose, and steviol-1,2-xylobioside is produced upon transfer of the additional sugar moiety;

(f) the precursor steviol glycoside is steviol-13-O-glucoside, the additional sugar moiety is rhamnose, and steviol-1,2-rhamnobioside is produced upon transfer of the additional sugar moiety;

(g) the precursor steviol glycoside is rebaudioside A, the additional sugar moiety is glucose, and rebaudioside D is produced upon transfer of the additional glucose moiety; or

(h) the precursor steviol glycoside is rubusoside, the additional sugar moiety is xylose, and 1,2-stevioxyloside is produced upon transfer of the sugar moiety.

3. The method of claim 1 , wherein the starting composition is further contacted with:

(a) a second 5′-UDP glycosyl transferase polypeptide capable of beta 1,2 glycosylation of the C2′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside;

(b) a 5′-UDP glycosyl transferase polypeptide capable of glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group;

(c) a 5′-UDP glycosyl transferase polypeptide capable of glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group; and/or

(d) a 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

4. The method of claim 3 , wherein at least one of the polypeptides is expressed in a recombinant host comprising one or more genes encoding the one or more polypeptides.

5. The method of claim 4 , wherein the sugar moiety donor comprises ADP-sugar, CDP-sugar, GDP-sugar, and/or UDP-sugar.

6. The method of claim 3 , wherein:

(a) the second 5′-UDP glycosyl transferase polypeptide comprises a polypeptide having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:5 or the amino acid sequence set forth in SEQ ID NO:76 or 78;

(b) the 5′-UDP glycosyl transferase polypeptide capable of glycosylating the steviol or the precursor steviol glycoside at its C-19 carboxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1;

(c) the 5′-UDP glycosyl transferase polypeptide capable of glycosylating the steviol or the precursor steviol glycoside at its C-13 hydroxyl group comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:3; and/or

(d) the 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside comprises a polypeptide having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:7.

7. The method of claim 1 , wherein the first recombinant 5′-UDP glycosyl transferase polypeptide is expressed by a recombinant host comprising a recombinant gene encoding the first recombinant 5′-UDP glycosyl transferase polypeptide.

8. The method of claim 1 , wherein the method is an in vitro method, further comprising supplying the sugar moiety donor or a cell-free system for regeneration of the sugar moiety donor.

9. The method of claim 8 , wherein the target steviol glycoside is or the target steviol glycoside composition comprises RebD, the starting composition comprises RebA as the precursor steviol glycoside, wherein the starting composition is contacted with the first recombinant 5′-UDP glycosyl transferase polypeptide in stoichiometric or excess amount relative to RebD.

10. The method of claim 8 , wherein the target steviol glycoside is or the target steviol glycoside composition comprises RebD, the starting composition comprises a stevia extract having at least one of RebA and stevioside as the precursor steviol glycoside,

wherein the starting composition is contacted with the first recombinant 5′-UDP glycosyl transferase polypeptide, a 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside and UDP-glucose in stoichiometric or excess amount relative to the steviol glycoside.

11. The method of claim 8 , wherein the target steviol glycoside is RebA, RebD, rebaudioside B (RebB), steviol-1,2-bioside, stevioside, rebaudioside E (RebE), dulcoside A, rebaudioside C (RebC), rebaudioside F (RebF), or a mixture of two or more of these compounds.

12. The method of claim 8 , wherein the first recombinant 5′-UDP glycosyl transferase polypeptide is provided in soluble form or in immobilized form.

13. The method of claim 8 , wherein the in vitro method is a whole cell in vitro method, wherein the whole cells are fed raw materials comprising the steviol and/or the precursor steviol glycoside.

14. The method of claim 13 , wherein the whole cells are fed raw materials comprising the steviol and/or the precursor steviol glycoside is derived from plant extract.

15. The method of claim 13 , wherein the whole cell used in the whole cell in vitro method is:

(a) in suspension or immobilized;

(b) entrapped in a calcium or sodium alginate bead;

(c) linked to a hollow fiber tube reactor system;

(d) concentrated and entrapped within a membrane reactor system; or (d)

(e) in fermentation broth or in a reaction buffer.

16. The method of claim 13 , further comprising permeabilizing the whole cell by using a permeabilizing agent, wherein the permeabilizing agent is a solvent, a detergent, or a surfactant, by a mechanical shock, an electroporation, or an osmotic shock.

17. The method of claim 13 , wherein the whole cell is microorganism being a prokaryote or a eukaryote.

18. The method of claim 13 , wherein the whole cell is an Escherichia coli cell, a Saccharomyces cerevisiae cell, or a Yarrowia lipolytica cell.

19. The method of claim 13 , wherein the starting composition further comprises steviol that is converted to RebA, RebD and/or RebE and the whole cell is a recombinant cell expressing:

(a) the first recombinant 5′-UDP glycosyl transferase polypeptide;

(b) a 5′-UDP glycosyl transferase polypeptide capable of glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group;

(c) a 5′-UDP glycosyl transferase polypeptide capable of glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group; and

(d) a 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

20. The method of claim 19 , wherein the recombinant cell further expresses a second 5′-UDP glycosyl transferase polypeptide capable of beta 1,2 glycosylation of the C2′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

21. The method of claim 13 , wherein RebA as the precursor steviol glycoside is converted to RebD as the target steviol glycoside and the whole cell is the recombinant cell expressing the first recombinant 5′-UDP glycosyl transferase polypeptide.

22. The method of claim 13 , wherein rubusoside or stevioside RebA as the precursor steviol glycoside is converted to RebD as the target steviol glycoside and the whole cell is a recombinant cell expressing:

(a) the first recombinant 5′-UDP glycosyl transferase polypeptide; and

(b) a 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

23. The method of claim 22 , wherein the recombinant cell further expresses a second 5′-UDP glycosyl transferase polypeptide capable of beta 1,2 glycosylation of the C2′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

24. The method of claim 13 , wherein steviol-13-O-glucoside (13-SMG) is converted to RebD and the whole cell is a recombinant cell expressing:

(a) the first recombinant 5′-UDP glycosyl transferase polypeptide;

(b) a 5′-UDP glycosyl transferase polypeptide capable of glycosylating steviol or the precursor steviol glycoside at its C-19 carboxyl group; and

(c) a 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

25. The method of claim 24 , wherein the recombinant cell further expresses a second 5′-UDP glycosyl transferase polypeptide capable of beta 1,2 glycosylation of the C2′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

26. The method of claim 13 , wherein steviol-19-O-glucoside (19-SMG) is converted to RebD and the whole cell is a recombinant cell expressing:

(a) the first recombinant 5′-UDP glycosyl transferase polypeptide;

(b) a 5′-UDP glycosyl transferase polypeptide capable of glycosylating steviol or the precursor steviol glycoside at its C-13 hydroxyl group; and

(c) a 5′-UDP glycosyl transferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

27. The method of claim 26 , wherein the recombinant cell further expresses a second 5′-UDP glycosyl transferase polypeptide capable of beta 1,2 glycosylation of the C2′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside.

28. A method of transferring an additional sugar moiety to a C2′ of the 13-O-glucose, the 19-O-glucose, or both the 13-O-glucose and the 19-O-glucose of a precursor steviol glycoside having a 13-O-glucose, a 19-O-glucose, or both a 13-O-glucose and a 19-O-glucose, comprising contacting the precursor steviol glycoside with a first recombinant uridine 5′-diphospho (UDP) glycosyl transferase polypeptide capable of beta 1,2 glycosylation of a C2′ of the 13-O-glucose, the 19-O-glucose, or both the 13-O-glucose and the 19-O-glucose of the precursor steviol glycoside and having at least 80% identity to the amino acid sequence set forth in SEQ ID NO:152 and one or more sugar moiety donor, under suitable reaction conditions to transfer of the additional sugar moiety to the precursor steviol glycoside;

wherein the precursor steviol glycoside is steviol-13-O-glucoside, rubusoside, stevioside or rebaudioside A; and

wherein stevioside, rebaudioside E, rebaudioside D, steviol-1,2 bioside, steviol-1,2-xylobioside, steviol-1,2-rhamnobioside, an isomer thereof, and/or a steviol glycoside composition thereof is produced upon transfer of the additional sugar moiety.

29. The method of claim 28 , wherein:

(a) the precursor steviol glycoside is rubusoside, the second additional sugar moiety is glucose, and stevioside is produced upon transfer of the additional second glucose moiety;

(b) the precursor steviol glycoside is stevioside, the second additional sugar moiety is glucose, and RebE is produced upon transfer of the additional second glucose moiety; and/or

(c) the steviol glycoside is RebA, the additional second sugar moiety is glucose and RebD is produced upon transfer of the additional second glucose moiety.

30. The method of claim 28 , wherein the starting composition comprising the precursor steviol glycoside is further contacted with:

(a) a second 5′-UDP glycosyltransferase polypeptide having at least 80% sequence identity to the amino acid sequence set forth in SEQ ID NO:5 or the amino acid sequence set forth in SEQ ID NO:76 or 78;

(b) a 5′-UDP glycosyltransferase polypeptide capable of glycosylating the steviol or the precursor steviol glycoside at its C-19 carboxyl group has the amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:1;

(c) a 5′-UDP glycosyltransferase polypeptide capable of glycosylating the steviol or the precursor steviol glycoside at its C-13 hydroxyl group has the amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:3; and/or

(d) a 5′-UDP glycosyltransferase polypeptide capable of beta 1,3 glycosylation of the C3′ of the 13-O-glucose, 19-O-glucose, or both 13-O-glucose and 19-O-glucose of the precursor steviol glycoside has the amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 7.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2025
From: HOUGHTON-LARSEN, JENS; HICKS, PAULA; NAESBY, MICHAEL; TANGE OSTERGAARD, THOMAS; HANSEN, JORGEN; DALGAARD, MICHAEL MIKKELSEN; HANSEN, ESBEN HALKJAER; SIMON, ERNESTO; TAVARES, SABINA
To: EVOLVA SA
Reel/Frame 072012/0407 →
MERGER Recorded Jun 18, 2024
From: EVOLVA AG
To: DANSTAR FERMENT AG
Reel/Frame 067762/0166 →
Continuity (11)
Continuation 17471615 · Sep 10, 2021
Continuation 16535373 · Aug 8, 2019
Continuation 15439660 · Feb 22, 2017
Division 14237540
Provisional Application 61521084 · Aug 8, 2011
Provisional Application 61521203 · Aug 8, 2011
Provisional Application 61521051 · Aug 8, 2011
Provisional Application 61523487 · Aug 15, 2011
Provisional Application 61567929 · Dec 7, 2011
Provisional Application 61603639 · Feb 27, 2012
Related Publication 20230407360A1 · Dec 21, 2023
References Cited (400)
US 4590160A · Nishihashi et al. · 1986 [cited by applicant]
US 5198360A · Ballou · 1993 [cited by applicant]
US 5204253A · Sanford et al. · 1993 [cited by applicant]
US 5306862A · Chappell et al. · 1994 [cited by applicant]
US 5460949A · Saunders et al. · 1995 [cited by applicant]
US 5538880A · Lundquist et al. · 1996 [cited by applicant]
US 6013863A · Lundquist et al. · 2000 [cited by applicant]
US 6215051B1 · Yu et al. · 2001 [cited by applicant]
US 6255557B1 · Brandle · 2001 [cited by applicant]
US 6284493B1 · Roth · 2001 [cited by applicant]
US 6284506B1 · Hoshino et al. · 2001 [cited by applicant]
US 6329571B1 · Hiei · 2001 [cited by applicant]
US 6586202B2 · Hoshino et al. · 2003 [cited by applicant]
US 6660507B2 · Cheng et al. · 2003 [cited by applicant]
US 6806076B1 · Miyake et al. · 2004 [cited by applicant]
US 6969595B2 · Brzostowicz et al. · 2005 [cited by applicant]
US 7034140B2 · Bramucci et al. · 2006 [cited by applicant]
US 7056717B2 · Cheng et al. · 2006 [cited by applicant]
US 7098000B2 · Cheng et al. · 2006 [cited by applicant]
US 7129392B2 · Hahn et al. · 2006 [cited by applicant]
US 7132268B2 · Miyake et al. · 2006 [cited by applicant]
US 7172886B2 · Keasling et al. · 2007 [cited by applicant]
US 7183089B2 · Keasling et al. · 2007 [cited by applicant]
US 7186891B1 · Chappell et al. · 2007 [cited by applicant]
US 7208298B2 · Miyake et al. · 2007 [cited by applicant]
US 7335815B2 · Boronat et al. · 2008 [cited by applicant]
US 7364885B2 · Miyake et al. · 2008 [cited by applicant]
US 7422884B2 · Bai et al. · 2008 [cited by applicant]
US 7514597B2 · Nakamura et al. · 2009 [cited by applicant]
US 7569389B2 · Feldmann et al. · 2009 [cited by applicant]
US 7692065B2 · Harper et al. · 2010 [cited by applicant]
US 7838287B2 · Goldsmith et al. · 2010 [cited by applicant]
US 7923541B2 · Yang et al. · 2011 [cited by applicant]
US 7927851B2 · Brandle et al. · 2011 [cited by applicant]
US 7981647B2 · Berry et al. · 2011 [cited by applicant]
US 9562251B2 · Kishore et al. · 2017 [cited by applicant]
US 10435730B2 · Houghton-Larsen · 2019 [cited by examiner]
US 10815514B2 · Olsson et al. · 2020 [cited by applicant]
US 10947515B2 · Boer et al. · 2021 [cited by applicant]
US 20020142408A1 · DiCosimo et al. · 2002 [cited by applicant]
US 20030033626A1 · Hahn et al. · 2003 [cited by applicant]
US 20030148416A1 · Berry et al. · 2003 [cited by applicant]
US 20030148479A1 · Keasling et al. · 2003 [cited by applicant]
US 20030190734A1 · Hoshino et al. · 2003 [cited by applicant]
US 20030219798A1 · Gokarn et al. · 2003 [cited by applicant]
US 20040010815A1 · Lange et al. · 2004 [cited by applicant]
US 20040072311A1 · DiCosimo et al. · 2004 [cited by applicant]
US 20040078846A1 · Desouza et al. · 2004 [cited by applicant]
US 20040176570A1 · Bacher et al. · 2004 [cited by applicant]
US 20040194162A1 · Hahn et al. · 2004 [cited by applicant]
US 20050003474A1 · Desouza et al. · 2005 [cited by applicant]
US 20050032169A1 · Miyake et al. · 2005 [cited by applicant]
US 20060014264A1 · Sauer et al. · 2006 [cited by applicant]
US 20060079476A1 · Keasling et al. · 2006 [cited by applicant]
US 20060083838A1 · Jackson et al. · 2006 [cited by applicant]
US 20070004000A1 · Miyake et al. · 2007 [cited by applicant]
US 20070077616A1 · Keasling et al. · 2007 [cited by applicant]
US 20070099261A1 · Keasling et al. · 2007 [cited by applicant]
US 20070128311A1 · Prakash et al. · 2007 [cited by applicant]
US 20070166782A1 · Keasling et al. · 2007 [cited by applicant]
US 20070202579A1 · Berry et al. · 2007 [cited by applicant]
US 20070238157A1 · Millis et al. · 2007 [cited by applicant]
US 20070238159A1 · Millis et al. · 2007 [cited by applicant]
US 20070238160A1 · Millis et al. · 2007 [cited by applicant]
US 20070254354A1 · Millis et al. · 2007 [cited by applicant]
US 20070269857A1 · Miyake et al. · 2007 [cited by applicant]
US 20070286850A1 · Bai et al. · 2007 [cited by applicant]
US 20080064063A1 · Brandle et al. · 2008 [cited by applicant]
US 20080081358A1 · Vittanen et al. · 2008 [cited by applicant]
US 20080131926A1 · Miyake et al. · 2008 [cited by applicant]
US 20080216397A1 · Busby et al. · 2008 [cited by applicant]
US 20080261280A1 · Hahn et al. · 2008 [cited by applicant]
US 20080271205A1 · Yamaguchi · 2008 [cited by examiner]
US 20080286870A1 · Vittanen et al. · 2008 [cited by applicant]
US 20080292775A1 · Prakash et al. · 2008 [cited by applicant]
US 20080318227A1 · Bacher et al. · 2008 [cited by applicant]
US 20090004724A1 · Keasling et al. · 2009 [cited by applicant]
US 20090047718A1 · Blaschek et al. · 2009 [cited by applicant]
US 20090055974A1 · Tanksley et al. · 2009 [cited by applicant]
US 20090074935A1 · Lee · 2009 [cited by applicant]
US 20090143308A1 · Monk et al. · 2009 [cited by applicant]
US 20090286262A1 · Slack · 2009 [cited by applicant]
US 20090298706A1 · Lee et al. · 2009 [cited by applicant]
US 20100112156A1 · Abelyan et al. · 2010 [cited by applicant]
US 20100120096A1 · Kitaoka et al. · 2010 [cited by applicant]
US 20100221801A1 · Van Dyk · 2010 [cited by applicant]
US 20100297722A1 · Anterola et al. · 2010 [cited by applicant]
US 20100316782A1 · Shi et al. · 2010 [cited by applicant]
US 20110087011A1 · Chiang et al. · 2011 [cited by applicant]
US 20110092684A1 · Abelyan et al. · 2011 [cited by applicant]
US 20110126318A1 · Allen et al. · 2011 [cited by applicant]
US 20110160311A1 · Prakash et al. · 2011 [cited by applicant]
US 20120021111A1 · Pfister et al. · 2012 [cited by applicant]
US 20120083593A1 · Liu et al. · 2012 [cited by applicant]
US 20120164678A1 · Stephanopoulos et al. · 2012 [cited by applicant]
US 20120178169A1 · Voytas et al. · 2012 [cited by applicant]
US 20130137138A1 · Hansen · 2013 [cited by applicant]
US 20130171328A1 · Kishore et al. · 2013 [cited by applicant]
US 20140329281A1 · Houghton-Larsen et al. · 2014 [cited by applicant]
US 20150159188A1 · Ono et al. · 2015 [cited by applicant]
US 20150342234A1 · Hicks et al. · 2015 [cited by applicant]
US 20210147815A1 · Boer et al. · 2021 [cited by applicant]
CN 101720910 · 2010 [cited by applicant]
CN 102216313 · 2011 [cited by applicant]
CN 103397064 · 2013 [cited by applicant]
EP 0955363 · 1999 [cited by applicant]
EP 1072683 · 2001 [cited by applicant]
EP 1171610 · 2007 [cited by applicant]
EP 1198575 · 2007 [cited by applicant]
EP 1383864 · 2008 [cited by applicant]
EP 1897951 · 2008 [cited by applicant]
EP 1947189 · 2008 [cited by applicant]
EP 1392824 · 2008 [cited by applicant]
EP 2575432 · 2013 [cited by applicant]
EP 2902410 · 2015 [cited by applicant]
JP 59101408 · 1984 [cited by applicant]
JP 3277275 · 1991 [cited by applicant]
JP 05115298 · 1993 [cited by applicant]
JP 2009034080 · 2009 [cited by applicant]
KR 1020120088035 · 2012 [cited by applicant]
KR 20150000258 · 2015 [cited by applicant]
WO WO1999018224 · 1999 [cited by applicant]
WO WO2000036081 · 2000 [cited by applicant]
WO WO2000037663 · 2000 [cited by applicant]
WO WO2000063400 · 2000 [cited by applicant]
WO WO2001012828 · 2001 [cited by applicant]
WO WO2001083769 · 2001 [cited by applicant]
WO WO2001094561 · 2001 [cited by applicant]
WO 2002024865 · 2002 [cited by applicant]
WO WO2002020728 · 2002 [cited by applicant]
WO WO2002020815 · 2002 [cited by applicant]
WO WO2002055709 · 2002 [cited by applicant]
WO WO2003008540 · 2003 [cited by applicant]
WO WO2004029255 · 2004 [cited by applicant]
WO WO2005079183 · 2005 [cited by applicant]
WO WO2006016395 · 2006 [cited by applicant]
WO WO2006069610 · 2006 [cited by applicant]
WO WO2006093289 · 2006 [cited by applicant]
WO WO2006096392 · 2006 [cited by applicant]
WO WO2007136847 · 2007 [cited by applicant]
WO WO2008008256 · 2008 [cited by applicant]
WO WO2008034648 · 2008 [cited by applicant]
WO WO2008039499 · 2008 [cited by applicant]
WO WO2008051349 · 2008 [cited by applicant]
WO WO2008091547 · 2008 [cited by applicant]
WO WO2009005704 · 2009 [cited by applicant]
WO WO2009037329 · 2009 [cited by applicant]
WO WO2009071277 · 2009 [cited by applicant]
WO WO2009086049 · 2009 [cited by applicant]
WO WO2009105612 · 2009 [cited by applicant]
WO WO2009108680 · 2009 [cited by applicant]
WO WO2009111513 · 2009 [cited by applicant]
WO 2009140394 · 2009 [cited by applicant]
WO WO2010021001 · 2010 [cited by applicant]
WO WO2010038911 · 2010 [cited by applicant]
WO WO2010044960 · 2010 [cited by applicant]
WO 2010142305 · 2010 [cited by applicant]
WO WO2010146463 · 2010 [cited by applicant]
WO WO2011028671 · 2011 [cited by applicant]
WO WO2011037959 · 2011 [cited by applicant]
WO WO2011046423 · 2011 [cited by applicant]
WO WO2011056834 · 2011 [cited by applicant]
WO 2011140329 · 2011 [cited by applicant]
WO 2011151326 · 2011 [cited by applicant]
WO 2011153378 · 2011 [cited by applicant]
WO WO2011153144 · 2011 [cited by applicant]
WO WO2012075030 · 2012 [cited by applicant]
WO WO2013019050 · 2013 [cited by applicant]
WO WO2013022989 · 2013 [cited by applicant]
WO WO2013076577 · 2013 [cited by applicant]
WO WO2013096420 · 2013 [cited by applicant]
WO WO2013102793 · 2013 [cited by applicant]
WO WO2013110673 · 2013 [cited by applicant]
WO WO2013176738 · 2013 [cited by applicant]
WO WO2014086890 · 2014 [cited by applicant]
WO WO2014122227 · 2014 [cited by applicant]
WO WO2014122328 · 2014 [cited by applicant]
WO 2014191580 · 2014 [cited by applicant]
WO 2015011209 · 2015 [cited by applicant]
WO 2015014959 · 2015 [cited by applicant]
WO 2015016393 · 2015 [cited by applicant]
WO WO2015014969 · 2015 [cited by applicant]
WO WO2015028324 · 2015 [cited by applicant]
WO WO2015132411 · 2015 [cited by applicant]
WO 2016023844 · 2016 [cited by applicant]
WO WO2016038095 · 2016 [cited by applicant]
WO WO2016120486 · 2016 [cited by applicant]
WO WO2017025362 · 2017 [cited by applicant]
WO WO2018083338 · 2018 [cited by applicant]
Pace et al. (Contribution of Hydrophobic Interactions to Protein Stability, J. Mol. Biol. 408 (2011): 514-28. (Year: 2011). [cited by examiner]
Kovylyaeva et al., Glycosides from Stevia rebaudiana, Chem. Nat. Compounds 43, 2007, 81-85. (Year: 2007). [cited by examiner]
Rellick et al., Comparison of van der Waals and semiempirical calculations of the molecular volumes of small molecules and proteins, Biopolymers: Original Research on Biomolecules 42.2, 1997, 191-202. (Year: 1997). [cited by examiner]
Liu et al., “Functional and Biochemical Characterization of [cited by applicant]
Sun et al., “Regulation and Function of [cited by applicant]
Bateman et al., “Pfam 3.1: 1313 multiple alignments and profile HMMs match the majority of proteins,” Nucleic Acids Res. 27(1):260-2 (Jan. 1999). [cited by applicant]
Bay & Turner, “Diversity and evolution of the small multidrug resistance protein family,” BMC Evol. Biol. 9:140 (Jun. 2009). [cited by applicant]
Brachmann et al., “Designer deletion strains derived from [cited by applicant]
Chen et al., “Transferring a biosynthetic cycle into a productive [cited by applicant]
Chenna et al., “Multiple sequence alignment with the Clustal series of programs,” Nucleic Acids Res. 31(13):3497-500 (Jul. 2003). [cited by applicant]
Del Sorbo et al., “Fungal transporters involved in efflux of natural toxic compounds and fungicides,” Fungal. Genet. Biol. 30(1):1-15 (Jun. 2000). [cited by applicant]
Diener et al., “ [cited by applicant]
GenBank Accession No. AAB62280, dated Jul. 2, 1997 (2 pages). [cited by applicant]
GenBank Accession No. AAB87091, dated Mar. 22, 2000 (2 pages). [cited by applicant]
GenBank Accession No. AAC28895.1, dated Aug. 6, 1998 (2 pages). [cited by applicant]
GenBank Accession No. AAC39505, dated Jul. 26, 1998 (1 page). [cited by applicant]
GenBank Accession No. AAD34294, dated Mar. 22, 2000 (2 pages). [cited by applicant]
GenBank Accession No. AAD34295, dated Mar. 22, 2000 (2 pages). [cited by applicant]
GenBank Accession No. AAD47596, dated Aug. 9, 1999 (2 pages). [cited by applicant]
GenBank Accession No. AAH69913, dated Jul. 15, 2006 (2 pages). [cited by applicant]
GenBank Accession No. AEE36246, dated Oct. 6, 2014 (3 pages). [cited by applicant]
GenBank Accession No. AAR06912, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. AAR06916.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. AAR06920.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. ABA42921, dated Jun. 21, 2006 (1 page). [cited by applicant]
GenBank Accession No. ABB88839, dated May 28, 2008 (2 pages). [cited by applicant]
GenBank Accession No. ABC59076, dated Jun. 6, 2007 (1 page). [cited by applicant]
GenBank Accession No. ABC98596, dated Jan. 31, 2014 (2 pages). [cited by applicant]
GenBank Accession No. ABD60225, dated May 28, 2008 (2 pages). [cited by applicant]
GenBank Accession No. ABD92926, dated Oct. 10, 2007 (2 pages). [cited by applicant]
GenBank Accession No. AC133334, dated Jan. 31, 2004 (44 pages). [cited by applicant]
GenBank Accession No. ACD93722, dated Jun. 10, 2008 (1 page). [cited by applicant]
GenBank Accession No. AF034774, dated Apr. 17, 1998 (2 pages). [cited by applicant]
GenBank Accession No. AY562490, dated May 23, 2006 (3 pages). [cited by applicant]
GenBank Accession No. BAA43200, dated Mar. 13, 1999 (2 pages). [cited by applicant]
GenBank Accession No. BAB59027, dated Jan. 30, 2002 (1 page). [cited by applicant]
GenBank Accession No. BAF61135, dated May 9, 2007 (2 pages). [cited by applicant]
GenBank Accession No. BAG30962, dated Nov. 12, 2012 (2 pages). [cited by applicant]
GenBank Accession No. BC153262, dated Oct. 4, 2007 (3 pages). [cited by applicant]
GenBank Accession No. CAA75568, dated Nov. 14, 2006 (2 pages). [cited by applicant]
GenBank Accession No. CAA76703, dated Nov. 14, 2006 (1 page). [cited by applicant]
GenBank Accession No. CAE09055, dated Nov. 14, 2006 (2 pages). [cited by applicant]
GenBank Accession No. CAG41604, dated Feb. 6, 2015 (2 pages). [cited by applicant]
GenBank Accession No. DQ398871.3, dated May 28, 2008 (2 pages). [cited by applicant]
GenBank Accession No. EDY51667, dated Sep. 2, 2008 (2 pages). [cited by applicant]
GenBank Accession No. EU263989, dated Jun. 11, 2008 (2 pages). [cited by applicant]
GenBank Accession No. NM_116512, dated Jan. 22, 2014 (3 pages). [cited by applicant]
GenBank Accession No. NP_001105097, dated Aug. 4, 2015 (2 pages). [cited by applicant]
GenBank Accession No. NP_013636.1 (YML075C), dated Jul. 16, 2015 (3 pages). [cited by applicant]
GenBank Accession No. NP_194183, dated Jan. 22, 2014 (4 pages). [cited by applicant]
GenBank Accession No. NP_195399, dated Jan. 22, 2014 (3 pages). [cited by applicant]
GenBank Accession No. NP_197872.1, dated Jan. 22, 2014 (2 pages). [cited by applicant]
GenBank Accession No. Q9UVY5.1, dated Apr. 1, 2015 (3 pages). [cited by applicant]
Garber et al., “Computational methods for transcriptome annotation and quantification using RNA-seq,” Nat Methods 8(6):469-77 (2011). [cited by applicant]
Kawai et al., “Transformation of [cited by applicant]
Lin et al., “Arrestin-related ubiquitin-ligase adaptors regulate endocytosis and protein turnover at the cell surface,” Cell 135(4):714-25 (2008). [cited by applicant]
Nagalakshmi et al., “The transcriptional landscape of the yeast genome defined by RNA sequencing,” Science 320(5881 ): 1344-9 (2008). [cited by applicant]
Nikko & Pelham, “Arrestin-mediated endocytosis of yeast plasma membrane transporters,” Traffic 10(12):1856-67 (2009). [cited by applicant]
Nikko et al. “Arrestin-like proteins mediate ubiquitination and endocytosis of the yeast metal transporter Smf1,” EMBO Rep. 9(12):1216-21 (2008). [cited by applicant]
Olsson et al., “Microbial production of next-generation stevia sweeteners,” Microbial Cell Factories, 15:11-14 (2016). [cited by applicant]
Partow et al., “Characterization of different promoters for designing a new expression vector in [cited by applicant]
Robinson & Oshlack et al., “A scaling normalization method for differential expression analysis of RNA-seq data,” Genome Bioi. 11(3):R25 (2010). [cited by applicant]
Saier Jr. et al., “The transporter classification database,” Nucl. Acids Res., 42(1):D251-258 (2014). [cited by applicant]
Wang et al., “RNA-Seq: a revolutionary tool for transcriptomics,” Nat Rev Genet. 10(1):57-63 (2009). [cited by applicant]
Wilhelm et al., “Defining transcribed regions using RNA-seq,” Nature Protocols 5:255-66 (2010). [cited by applicant]
Yang Quanhua et.al., “Analysis of the Chemical constituents of Stevia rebaudiana and its sweetness,” Journal of Beijing University of Chemical Technology, vol. 39, No. 2., p. 28-32 (2012) (English Abstract). [cited by applicant]
Ceunen & Geuns, “Steviol glycosides: chemical diversity, metabolism, and function,” J. Nat. Prod. 76(6):1201-28 (Jun. 2013). [cited by applicant]
Olsson et al., “Microbial production of next-generation stevia sweeteners,” Microbial Cell Factories, 15:1-14 (2016). [cited by applicant]
Song et al., “The Aspergillus fumigatus 1-29 damage resistance protein family coordinately regulates ergosterol biosynthesis and azole susceptibility,” MBIO, 7:1-13 (2016). [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 14/648,747, mailed Mar. 23, 2017, pp. 1-20. [cited by applicant]
Third Party Observation in EP Application No. 13801569.8; mailed Apr. 26, 2017, pp. 1-5. [cited by applicant]
Final Office Action for U.S. Appl. No. 14/648,747, mailed Sep. 6, 2017 (pp. 1-19). [cited by applicant]
Third Party Observation in EP Application No. 13801569.8; mailed Oct. 23, 2017, pp. 1-6. [cited by applicant]
International Preliminary Report on Patentability from the International Bureau for International Application PCT/EP2015/070620; mailed Mar. 14, 2017 (pp. 1-25). [cited by applicant]
Third Party Submission in U.S. Appl. No. 15/506,196; dated Mar. 9, 2018 pp. 1-68. [cited by applicant]
International Preliminary Report on Patentability from the International Bureau for International Application PCTEP2015/068314; mailed Feb. 14, 2017 (pp. 1-10). [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/EP2015/052007; mailed Jul. 4, 2016, pp. 1-24. [cited by applicant]
International Preliminary Report on Patentability from the International Bureau for International Application PCT/EP2015/052007; mailed Aug. 1, 2017 (pp. 1-16). [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/EP2016/068259; mailed Jan. 24, 2017, pp. 1-18. [cited by applicant]
International Preliminary Report on Patentability from the International Bureau for International Application PCT/EP2016/068259; mailed Feb. 13, 2018 (pp. 1-11). [cited by applicant]
International Search Report and Written Opinion of International Search Authority for International Application No. PCTEP2016/080516; mailed Mar. 15, 2017, pp. 1-22. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/EP2017/061775; mailed Sep. 6, 2017, pp. 1-17. [cited by applicant]
International Search Report and Written Opinion of International Search Authority for International Application No. PCTEP2017/059028; mailed Jun. 27, 2017, pp. 1-15. [cited by applicant]
International Search Report and Written Opinion of International Search Authority for International Application No. PCT/EP2017/055589; mailed May 12, 2017, pp. 1-18. [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/EP2017/078473; mailed Jan. 25, 2018, pp. 1-16. [cited by applicant]
Mahe et al., “The ATP Binding Cassette Transporters Pdr5 and Snq2 of [cited by applicant]
Starratt et al., “Rebaudioside F, a diterpene glycoside from Stevia redaudiana”, Phytochemistry, 59(4):367-370. (Feb. 2002). Abstract. [cited by applicant]
Uniprot Accession No. Q75183, dated Jul. 5, 2004 (pp. 1-2). [cited by applicant]
Uniprot Accession No. Q75183, dated Jul. 22, 2008 (pp. 1-4). [cited by applicant]
Ohta et al., MassBank Accession No. FU000299 (May 2016). [cited by applicant]
Ohta et al., MassBank Accession No. FU000332 (May 2016). [cited by applicant]
Communication pursuant to Rules 161(1) and 162 EPC for European Application No. 14702889.8, dated Oct. 14, 2015 (2 pages). [cited by applicant]
Communication pursuant to Article 94(3) EPC in European Application No. 14 702 889.8; dated Jul. 27, 2016, pp. 1-5. [cited by applicant]
Third Party Submission in U.S. Appl. No. 14/648,747; dated Mar. 28, 2016, pp. 1-231. [cited by applicant]
International Search Report of the International Searching Authority for International Application No. PCT/EP2017/061774; mailed Aug. 30, 2017, pp. 1-20. [cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/EP2017/061774; mailed Aug. 30, 2017, pp. 1-13. [cited by applicant]
Shao et al., “Crystal structures of a multifunctional triterpene/flavonoid glycosyltransferase from Medicago truncatula,” Plant Cell 17(11):3141-54 (2005). [cited by applicant]
Shibata et al., “Glucosylation of Steviol and Steviol-Glucosides in Extracts from Stevia rebaudiana Bertoni” Plant Physiol. 95(1):152-56 (1991). [cited by applicant]
Singh et al., “Compendium of Transgenic Crop Plants: Transgenic Sugar, Tuber and Fiber,” Ed. Kole & Hall, Blackwell Publishing Ltd. pp. 97-115 (2008). [cited by applicant]
U.S. Food and Drug Administration GRAS Notice 323, “GRAS Assessment of High Purity Steviol Glycosides; Food Usage Conditions for General Recognition of Safety for PureCircle USA, Inc.,” pp. 1-262 (Feb. 2010). [cited by applicant]
U.S Food and Drug Administration GRAS Notice Notice 329, “Notice to the U.S. Food and Drug Administration that the use of RebpureTM (Rebaudioside A) derived from Stevia rebaudiana, as a Food Ingredient is Generally Reco… [cited by applicant]
Van Ooyen et al., “Heterologous protein production in the yeast [cited by applicant]
Vazquez De Aldana et al., “Nucleotide sequence of the exo-1,3-beta-glucanase-encoding gene, EXG1, of the yeast [cited by applicant]
Verwaal et al., “High-Level Production of Beta-Carotene in [cited by applicant]
Wallin, “Steviol Glycosides,” Chem. Tech Assessment—63rd JECFA, pp. 1-5 (2004). [cited by applicant]
Wallin, “Steviol Glycosides,” Chem. Tech Assessment—69th JECFA, pp. 1-7 (2007). [cited by applicant]
Wallner & Elofsson, “Can correct protein models be identified?,” Protein Sci. 12(5):1073-86 (May 2003). [cited by applicant]
Wang, “Structure, mechanism and engineering of plant natural product glycosyltransferases,” FEBS Letters 583(20):3303-9 (2009). [cited by applicant]
Xu et al., “Generation of hepatitis B virus PreS2-S antigen in Hansenula polymorpha,” Virol Sin. 29(6):403-9 (Dec. 2014). [cited by applicant]
Yadav et al., “A review on the improvement of stevia [Stevia rebaudiana (Bertoni)],” Can J Plant Sci. 91:1-27 (2011). [cited by applicant]
Yao et al., “A genetic linkage map for Stevia rebaudiana,” Genome 42:657-61 (1999). [cited by applicant]
Yazaki, “Abc transporters involved in the transport of plant secondary metabolites,” FEBS Lett. 580(4):1183-91 (Feb. 2006). [cited by applicant]
Yu et al., “Bioconversion of ethyl 4-chloro-3-oxobutanoate by permeabilized fresh brewer's yeast cells in the presence of allyl bromide,” J Ind Microbiol Biotechnol. 34(2)151-6 (2007). [cited by applicant]
Yuan et al., “Kinetics and activation parameters for oxidations of styrene by Compounds I from the cytochrome P450 (BM-3) (CYP102A1) heme domain and from CYP119,” Biochemistry 48(38):9140-6 (Sep. 2009). [cited by applicant]
Zheng et al. “An efficient one-step site-directed and site-saturation mutagenesis protocol,” Nucleic Acids Res. 32(14):e115 (Aug. 2004). [cited by applicant]
Zhu et al., “A multi-omic map of the lipid-producing yeast [cited by applicant]
GenBank Accession No. AAF61439.1, dated Sep. 25, 2000 (2 pages). [cited by applicant]
GenBank Accession No. AAM53963.1, dated Jun. 17, 2002 (2 pages). [cited by applicant]
GenBank Accession No. AAR06918.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. AAT93110.1, dated Apr. 24, 2007 (2 pages). [cited by applicant]
GenBank Accession No. ACE87855.1, dated Jun. 24, 2008 (1 page). [cited by applicant]
GenBank Accession No. ACM47734.1, dated Feb. 7, 2009 (1 page). [cited by applicant]
GenBank Accession No. ACT33422.1, dated Jul. 17, 2009 (1 page). [cited by applicant]
GenBank Accession No. AF515727.1, dated Jun. 17, 2002 (2 pages). [cited by applicant]
GenBank Accession No. AY345974.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. AY345978.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
Genbank Accession No. AY345980.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. AY345982.1, dated Dec. 28, 2004 (2 pages). [cited by applicant]
GenBank Accession No. BG521726.1, dated May 13, 2000 (2 pages). [cited by applicant]
GenBank Accession No. CAA23011.1, dated Oct. 23, 2008 (2 pages). [cited by applicant]
GenBank Accession No. CAA46815.1, dated Apr. 18, 2005 (2 pages). [cited by applicant]
GenBank Accession No. DQ269454.4, dated May 28, 2008 (2 pages). [cited by applicant]
GenBank Accession No. EU722415.1, dated Jun. 10, 2008 (2 pages). [cited by applicant]
GenBank Accession No. EU751291.1, dated Jun. 24, 2008 (2 pages). [cited by applicant]
EBI Accession No. AAY05902, “Jerusalem artichoke in-chain hydroxylase CYP81B1” (1 page), Jun. 15, 2009. [cited by applicant]
EBI Accession No. ABM86477, “Rice abiotic stress responsive polypeptide SEQ ID No. 4723” (1 page), dated Jun. 2, 2005. [cited by applicant]
UniProt Accession No. F2DG34, May 2011 (pp. 1-4). [cited by applicant]
UniProt Accession No. Q6VAA8, 2004 (pp. 1-6). [cited by applicant]
UniProt Accession No. Q7FPQ4, 2004 (pp. 1-6). [cited by applicant]
Jewett et al. “An integrated cell-free metabolic platform for protein production and synthetic biology,” Mol Syst Biol. 4:220 (2008). [cited by applicant]
Johnstone et al., “Cloning an Aspergillus nidulans developmental gene by transformation,” EMBO J. 4(5):1307-11 (1985). [cited by applicant]
Khoury et al., “Computational design of Candida boidinii xylose reductase for altered cofactor specificity,” Protein Sci. 18(10):2125-38 (Oct. 2009). [cited by applicant]
Kim et al., “Hydroxylation of ent-Kaurenoic Acid to Steviol in Stevia rebaudiana Bertoni-Purification and Partial Characterization of the Enzyme,” Arch Biochem Biophys. 332(2):223-30 (1996). [cited by applicant]
Kim & Shibata, “Characterization of ent-kaurenoic acid 13-hydroxylase in steviol biosynthesis of Stevia rebaudiana Bertoni,” Journal of the Korean Agriculturalchemical Society 40(6):501-7 (1997). [cited by applicant]
Knowles et al., “Genetic Transformation and Plant Regeneration in Stevia rebaudiana Using Microprojectile Bombardment,” In Vitro Cellular & Developmental Biology 39(abstract):23-A (2003). [cited by applicant]
Kohda et al., “New Sweet Diterpene glucoside from Stevia Rebaudiana,” Phytochemistry 15(6):981-3 (1976). [cited by applicant]
Kondo et al., “Preparation of high activity whole cell biocatalyst by permeabilization of recombinant flocculent yeast with alcohol,” Enzyme Microb Technol. 27(10), 806-11 (2000). [cited by applicant]
Kumar et al., “A comprehensive analysis of fifteen genes of steviol glycosides biosynthesis pathwayin Stevia rebaudiana (Bertoni)” Gene 492:276-84 (Epub Oct. 20, 2011). [cited by applicant]
Kusama et al., “Transglucosylation into stevioside by the enzyme system from [cited by applicant]
Li et al., “Crystal structure of Medicago truncatula UGT85H2—insights into the structural basis of a multifunctional (iso) flavonoid glycosyltransferase,” J Mol Biol. 370(5):951-63 (2007). [cited by applicant]
Li et al., “Systematic Mutational Analysis of Peptide Inhibition of the p53-MDM2/MDMX,” J Mol Biol. 398(2):200-13 (2010). [cited by applicant]
Li et al., “High-density cultivation of oleaginous yeast [cited by applicant]
Liu et al., “Preparation of high-activity whole cell biocatalysts by permeabilization of recombinant yeasts with alcohol,” J Biosci Bioeng. 89(6):554-8 (2000). [cited by applicant]
Ma et al., “Molecular cloning and characterization of Stevia Rebaudiana UDP-glucosyltransferase,” Acta Biologiae Experimentalis Sinica 36(2):123-9 (2003). [cited by applicant]
Ma “Part 1. Molecular Cloning and Functional Analysis of UDPG Glucosyltransferase Gene. Part 2. Molecular Cloning, Sequence Analysis and Evolution of Actin and EF1a Genes in Stevia Rebaudiana.” Chinese Doctor and Master… [cited by applicant]
Madan et al., “Stevia rebaudiana (Bert.) Bertoni—A Review,” Indian Journal of Natural Products and Resources 1(3):267-86 (2010). [cited by applicant]
Madhav et al., “Functional and structural variation of uridine diphosphate glycosyltransferase (UGT) gene of Stevia rebaudiana—UGTSr involved in the synthesis of rebaudioside A,” Plant Physiol. Biochem. 63:245-53 (Feb. … [cited by applicant]
Malonek et al., “The NADPH-cytochrome P450 Reductase Gene from Gibberalla fujikuroi is Essential for Gibberellin Biosynthesis,” J Bio Chem. 279(24):25075-84 (2004). [cited by applicant]
Mantovaneli et al., “The effect of temperature and flow rate on the clarification of the aqueous stevia-extract in a fixed-bed column with zeolites,” Braz J Chem Eng. 21(3):449-58 (2004). [cited by applicant]
Mattanovich et al., “Recombinant protein production in yeasts,” Methods Mol Biol. 824:329-58 (2012). [cited by applicant]
Megeji et al., “Introducing Stevia rebaudiana, a natural zero-calorie sweetener,” Current Science 88(5):801-4 (2005). [cited by applicant]
Mohamed et al., “UDP-dependent glycosyltransferases involved in the biosynthesis of steviol glycosides” Journal of Plant Physiology 168(10):1136-1141 (Jul. 2011; Epub Apr. 7, 2011). [cited by applicant]
Mumberg et al., “Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds,” Gene 156(1):119-22 (1995). [cited by applicant]
Naesby et al., “Yeast artificial chromosomes employed for random assembly of biosynthetic pathways and production of diverse compounds in [cited by applicant]
Naglak & Wang, “Rapid protein release from [cited by applicant]
Nakagiri et al., “cDNA cloning, functional expression and characterization of ent-copalyl diphosphate synthase from [cited by applicant]
Nelson et al., “P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature,” Pharmacogenetics 6:1-42 (1996). [cited by applicant]
Newman et al., “High-level production of amorpha-4, 11-diene in a two-phase partitioning bioreactor of metabolically engineered [cited by applicant]
Nicaud, “Yarrowia lipolytica,” Yeast 29(10):409-18 (Oct. 2012). [cited by applicant]
Nielsen et al., “Efficient PCR-based gene targeting with a recyclable marker for Aspergillus nidulans,” Fungal Genet Biol. 43(1):54-64 (2006). [cited by applicant]
Nour-Eldin et al., “USER cloning and USER fusion: the ideal cloning techniques for small and big laboratories,” Methods Mol Biol. 643:185-200 (2010). [cited by applicant]
Ohta et al., “Characterization of Novel Steviol Glycosides from Leaves of Stevia rebaudiana Morita,” J. Applied Glycosides 57(3):199-209 (Mar. 2010). [cited by applicant]
Ohta et al., MassBank Accession No. FU000341 (May 2011). [cited by applicant]
Ohta et al., MassBank Accession No. FU000342 (May 2011). [cited by applicant]
Ohta et al., MassBank Accession No. FU000343 (May 2011). [cited by applicant]
Ohtani et al., “Further Study on the 1,4-alpha-Transglucosylation of Rubusoside, a Sweet Steviol-Bisglucoside from Rubus suavissimus,” Agric Biol Chem. 55(2):449-53 (1991). [cited by applicant]
Oka & Jigami, “Reconstruction of de novo pathway for synthesis of UDP-glucuronic acid and UDP-xylose from intrinsic UDP-glucose in [cited by applicant]
Orihara et al., “Biotransformation of steviol by cultured cells of eucalyptus perriniana and Coffea Arabica,” Phytochemistry 30(12):3989-92 (1991). [cited by applicant]
Paradise et al., “Redirection of flux through the FPP branch-point in [cited by applicant]
Pearson & Lipman, “Improved tools for biological sequence comparison,” Proc Natl Acad Sci. 85(8):2444-8 (1998). [cited by applicant]
Piirainen et al., “Glycoengineering of yeasts from the perspective of glycosylation efficiency,” N Biotechnol. 31(6):532-7 (Dec. 2014). [cited by applicant]
Pompon et al., “Yeast Expression of Animal and Plant P450s in Optimized RedoxEnvironments,” Methods Enzymol 272:51-64 (1996). [cited by applicant]
Prelich, “Gene overexpression: uses, mechanisms, and interpretation,” Genetics 190(3):841-54 (Mar. 2012). [cited by applicant]
Presecki & Vasic-Racki, “Production of L-malic acid by permeabilized cells of commercial [cited by applicant]
Ro et al., “Production of the antimalarial drug precursor artemisinic acid in engineered yeast,” Nature 440(7086):940-3 (2006). [cited by applicant]
Saenge et al., “Potential use of oleaginous red yeast [cited by applicant]
Schwab et al., Poster, “Watchmaker®—Compound Generation by Combinatorial Genetics and Screening in Yeast,” 141st Annual Conference in St. Louis, 2008, 1 page. [cited by applicant]
Sen et al., “Developments in Directed Evolution for Improving Enzyme Functions,” Appl Biochem Biotechnol. 143(3):212-23 (2007). [cited by applicant]
Senthilraja et al., “RNA secondary structure prediction: Analysis of [cited by applicant]
Broun et al., “Catalytic plasticity of fatty acid modification enzymes underlying chemical diversity of plant lipids,” Science, vol. 282: 1315-1317 (1998). [cited by applicant]
Cheng, “Food Biotechnology,” Inner Mongolia Science and Technology Press (2008). (Book). [cited by applicant]
Devos et al., “Practical limits of function prediction,” Proteins: Structure, Function, and Genetics, vol. 41: 98-107 (2000). [cited by applicant]
Seffernick et al., “Melamine deaminase and Atrazine chlorohydrolase: 98 percent identical but functionally different,” J. Bacterial., vol. 183 (8): 2405-2410 (2001). [cited by applicant]
Whisstock et al., “Prediction of protein function from protein sequence,” Q. Rev. Biophysics., vol. 36 (3): 307-340 (2003). [cited by applicant]
Witkowski et al., “Conversion of b-ketoacyl synthase to a Malonyl Decarboxylase by replacement of the active cysteine with glutamine,” Biochemistry, vol. 38: 11643-11650 (1999). [cited by applicant]
Pearson, et al., “Improved tools for biological sequence comparison,” Proc Natl Acad Sci. 85(8):2444-8 (1988). [cited by applicant]
GenBank Accession No. XM_001467423, dated Jul. 16, 2015 (2 pages). [cited by applicant]
GenBank Accession No. XP_002282091, dated Dec. 7, 2011 (1 page). [cited by applicant]
SenBank Accession No. XP_002288339, dated Jul. 15, 2009 (2 pages). [cited by applicant]
GenBank Accession No. XP_002311286, dated Dec. 31, 2013 (2 pages). [cited by applicant]
GenBank Accession No. ZP_05004570, dated Jun. 8, 2010 (2 pages). [cited by applicant]
Gossen & Bujard, “Studying gene function in eukaryotes by conditional gene inactivation,” Annu. Rev. Genet. 36:153-73 (Jun. 2002). [cited by applicant]
Gritz & Davies, “Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B phosphotransferase gene and its expression in [cited by applicant]
Hallstrom & Moye-Rowley, “Divergent transcriptional control of multidrug resistance genes in [cited by applicant]
Katzmann et al., “Expression of an ATP-binding cassette transporter-encoding gene (YOR1) is required for bligomycin resistance in [cited by applicant]
Li et al., “Phylogenetic analysis of the UDP-glycosyltransferase multigene family of [cited by applicant]
Masada et al., “An efficient chemoenzymatic production of small molecule glucosides with in situ UDP-glucose recycling,” FEBS Lett. 581(13):2562-6 (May 2007). [cited by applicant]
Morita et al., “Japanese morning glory dusky mutants displaying reddish-brown or purplish-gray flowers are deficient in a novel glycosylation enzyme for anthocyanin biosynthesis, UDP-glucose:anthocyanidin 3-O-glucoside-… [cited by applicant]
Nagy et al., “Role of the yeast ABC transporter Yor1p in cadmium detoxification,” Biochimie 88(11):1665-71 (Jun. 2006). [cited by applicant]
Nikaido & Takatsuk, “Mechanisms of RND multidrug efflux pumps,” Biochim. Biophys. Acta. 1794(5):769-81 (May 2009). [cited by applicant]
Osmani et al., “Catalytic key amino acids and UDP-sugar donor specificity of a plant glucuronosyltransferase, UGT94B1: molecular modeling substantiated by site-specific mutagenesis and biochemical analyses,” Plant Physi… [cited by applicant]